Approval of YONDELIS® (trabectedin) by the Thai FDA for patients who have failed prior treatment with anthracyclines and ifosfamide or for those who are unsuited to receive these agents1
YONDELIS provides an additional treatment option for Thai adults diagnosed with advanced soft tissue sarcoma
Eligible adult patients in Thailand with advanced soft tissue sarcoma will have access to YONDELIS from 1st December 2026
SINGAPORE, Nov. 16, 2026 /PRNewswire/ — Independent biopharmaceutical company Specialised Therapeutics announced that the Thailand Food and Drug Administration approved YONDELIS® (trabectedin) on 24 July 2026 for the treatment of adult patients with advanced soft tissue sarcoma (STS).1
